Hepatocellular carcinoma in tyrosinemia type 1 without clear increase of AFP

Pediatrics. 2015 Mar;135(3):e749-52. doi: 10.1542/peds.2014-1913. Epub 2015 Feb 9.

Abstract

Patients with hereditary tyrosinemia type 1 have an elevated risk of developing hepatocellular carcinoma, especially if initiation of treatment with 2-(2-nitro-4-trifluoro-methylbenzoyl)-1,3-cyclohexanedione is delayed. Hepatocellular carcinoma can usually be suspected when there are increased α1-fetoprotein levels and characteristic imaging features. The present case shows that a lack of a clear increase in α1-fetoprotein should still lead to consideration of liver transplantation when imaging features change.

Keywords: 2-(2-nitro-4-trifluoro-methylbenzoyl)-1,3-cyclohexanedione; NTBC; hepatocellular carcinoma; tyrosinemia type 1; α-fetoprotein.

Publication types

  • Case Reports

MeSH terms

  • Biomarkers, Tumor / blood
  • Carcinoma, Hepatocellular / blood
  • Carcinoma, Hepatocellular / diagnosis
  • Carcinoma, Hepatocellular / etiology*
  • Diagnosis, Differential
  • Female
  • Follow-Up Studies
  • Humans
  • Infant
  • Liver Neoplasms / blood
  • Liver Neoplasms / diagnosis
  • Liver Neoplasms / etiology*
  • Magnetic Resonance Imaging
  • Tyrosinemias / blood
  • Tyrosinemias / complications*
  • Tyrosinemias / diagnosis
  • alpha-Fetoproteins / metabolism*

Substances

  • AFP protein, human
  • Biomarkers, Tumor
  • alpha-Fetoproteins